Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could popular Weight-Loss drugs also fight gum disease?

NCT ID NCT07770906

Disease control Sponsor: Cukurova University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This trial asks whether GLP-1 receptor agonists, a class of drugs used for weight management, can improve gum health and boost the response to standard deep-cleaning treatment in people with obesity and periodontitis. Adults with both conditions will be split into two groups: those who have used a GLP-1 drug for at least three months and those who have not. Everyone receives the same non-surgical periodontal therapy, and researchers compare gum measurements and inflammatory markers before treatment and at three and six months afterward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist (a class of weight-management drugs) combined with non-surgical periodontal therapy (deep cleaning of the gums)
What this could lead to
If GLP-1 drugs help, they could point to a way to improve gum treatment outcomes in people with obesity and periodontitis.
What could go wrong
This is a small, early-stage study. Results may not apply to everyone, and the exact benefits of GLP-1 drugs on gum health remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years * Body mass index (BMI) ≥25 kg/m² * Presence of at least 20 functional teeth * Diagnosis of periodontitis * For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months Exclusion Criteria: * Age between 18 and 65 years * Body mass index (BMI) ≥25 kg/m² * Presence of at least 20 functional teeth * Diagnosis of periodontitis * For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight Periodontal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.